rhinox 0.25 mg/ ml
orifarm healthcare a/s - oksymetazolinhydroklorid - nesespray, oppløsning - 0.25 mg/ ml
rhinox 0.5 mg/ ml
orifarm healthcare a/s - oksymetazolinhydroklorid - nesespray, oppløsning - 0.5 mg/ ml
zycomb 0.5 mg/ ml / 0.6 mg/ ml
orifarm healthcare a/s - xylometazolinhydroklorid / ipratropiumbromid - nesespray, oppløsning - 0.5 mg/ ml / 0.6 mg/ ml
zymelin 1 mg/ ml
orifarm healthcare a/s - xylometazolinhydroklorid - nesespray, oppløsning - 1 mg/ ml
zymelin 0.5 mg/ ml
orifarm healthcare a/s - xylometazolinhydroklorid - nesespray, oppløsning - 0.5 mg/ ml
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andre antineoplastiske midler - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
luxturna
novartis europharm limited - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna er indisert for behandling av voksne og paediatric pasienter med synstap på grunn av arvelig retinal dystrofi forårsaket av bekreftet biallelic rpe65 mutasjoner, og som har tilstrekkelig levedyktige celler retinal.
xylometazolinhydroklorid norfri 1 mg/ ml
evolan pharma ab - xylometazolinhydroklorid - nesespray, oppløsning - 1 mg/ ml
xylometazolinhydroklorid norfri 0.5 mg/ ml
evolan pharma ab - xylometazolinhydroklorid - nesespray, oppløsning - 0.5 mg/ ml
zabdeno
janssen-cilag international n.v. - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemoragisk feber, ebola - vaksiner - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.